EUVIMEDEUVIMED entdecken
Crossref

140-OR: Durable Glycemic Control and Elimination of Exogenous Insulin Use with VX-880 in Patients with Type 1 Diabetes (T1D)—VX-880-101 (FORWARD)

MICHAEL R. RICKELS, PIOTR WITKOWSKI, TREVOR W. REICHMAN, EELCO J. DE KONING, JAMES F. MARKMANN, JON S. ODORICO, MARTIN WIJKSTROM, LESLIE S. KEAN, CHANTAL MATHIEU, ANNE L. PETERS, YAOYUAN VINCENT TAN, KRISTINE VANIJCHAROENKARN und 5 weitere

Diabetes · 20.06.2025 · 74 (Supplement_1)

DOI: 10.2337/db25-140-or ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 20.06.2025. Verfasst von MICHAEL R. RICKELS und 16 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: VX-880 is an allogeneic stem cell-derived, fully differentiated islet cell therapy in clinical development for T1D.

Methods

This single-arm, open-label, phase 1/2/3 trial is evaluating VX-880 in T1D adults with impaired hypoglycemia awareness and ≥2 severe hypoglycemic episodes (SHEs) the year before enrollment. Participants receive a standard immunosuppression regimen. Enrollment and dosing in the phase 1/2 portion has completed and phase 3 is ongoing.

Results

These results reflect 12 participants who received a full VX-880 dose as a single infusion and were followed for at least one year, as of October 2024. At baseline, all participants had multiple SHEs and undetectable fasting C-peptide. All 12 participants demonstrated engraftment with glucose responsive C-peptide production at Day (D)90 MMTT which was durable through Month (M)12. All 12 participants achieved ADA HbA1c target of <7% (mean: baseline=7.8%; M12=6.0%) and time in range target of >70% (mean: baseline=49.5%; M12=93%); and all were free of SHEs from D90 onwards. All 12 participants had reduction in exogenous insulin use (mean reduction: 92%) and 10/12 (83%) no longer required exogenous insulin at M12. Median duration free of exogenous insulin was 232 (69 to 441) days. All 12 participants were evaluable for and achieved the phase 1/2 primary endpoint of elimination of SHEs and HbA1c <7%. Most adverse events (AEs) were mild or moderate in severity. There were no VX-880-related serious AEs. Two deaths occurred; both were reported previously and unrelated to VX-880. Overall, the safety profile was consistent with the immunosuppressive regimen and islet infusion procedure.

Conclusion

These durable clinical benefits of VX-880 with elimination of SHEs, improved glycemic control, and freedom from exogenous insulin support the curative potential of VX-880, the first and only allogeneic, stem-cell derived, islet cell therapy in pivotal development. Disclosure M.R. Rickels: Consultant; Vertex Pharmaceuticals Incorporated, Sernova, Corp. Research Support; Dompé, Tandem Diabetes Care, Inc. Consultant; Novo Nordisk. P. Witkowski: Advisory Panel; Vertex Pharmaceuticals Incorporated. Research Support; Sernova, Corp. Stock/Shareholder; Eledon. T.W. Reichman: Research Support; Vertex Pharmaceuticals Incorporated. Advisory Panel; Novo Nordisk. E.J. de Koning: None. J.F. Markmann: Consultant; iTolerance, Inc, Vertex Pharmaceuticals Incorporated. J.S. Odorico: Other Relationship; Regenerative Medical Solutions, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Other Relationship; Vertex Pharmaceuticals Incorporated, Veloxis. Research Support; National Institute of Diabetes and Digestive and Kidney Diseases. Consultant; UpToDate, Sernova, Corp. M. Wijkstrom: Consultant; Vertex Pharmaceuticals Incorporated. L.S. Kean: Consultant; Vertex Pharmaceuticals Incorporated. Research Support; Bristol-Myers Squibb Company, Tessera, Gilead Sciences, Inc, Novartis Pharmaceuticals Corporation. Advisory Panel; HiFi Bio. Research Support; Tonix, Merck & Co., Inc. C. Mathieu: Advisory Panel; Novo Nordisk, Sanofi, Eli Lilly and Company, Abbott, Medtronic, SAB Biotherapeutics, Inc, Roche Diabetes Care, Vertex Pharmaceuticals Incorporated, Biomea Fusion, Bayer Pharmaceuticals, Inc. A.L. Peters: Advisory Panel; Medscape. Consultant; Vertex Pharmaceuticals Incorporated. Research Support; Insulet Corporation, Abbott. Other Relationship; Omada Health. Y. Tan: None. K. Vanijcharoenkarn: None. D. Melton: Employee; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Sana Biotechnology. F. Pagliuca: Employee; Vertex Pharmaceuticals Incorporated. B. Bruinsma: Employee; Vertex Pharmaceuticals Incorporated. G. Marigowda: Employee; Vertex Pharmaceuticals Incorporated. C. Ricordi: Advisory Panel; Vertex Pharmaceuticals Incorporated, Novo Nordisk.

Zitieren

APA

RICKELS, M. R., WITKOWSKI, P., REICHMAN, T. W., KONING, E. J. D., MARKMANN, J. F., ODORICO, J. S., WIJKSTROM, M., KEAN, L. S., MATHIEU, C., PETERS, A. L., TAN, Y. V., VANIJCHAROENKARN, K., MELTON, D., PAGLIUCA, F., BRUINSMA, B., MARIGOWDA, G., & RICORDI, C. (2025). 140-OR: Durable Glycemic Control and Elimination of Exogenous Insulin Use with VX-880 in Patients with Type 1 Diabetes (T1D)—VX-880-101 (FORWARD). Diabetes, 74(Supplement_1). https://doi.org/10.2337/db25-140-or

Vancouver

RICKELS MR, WITKOWSKI P, REICHMAN TW, KONING EJD, MARKMANN JF, ODORICO JS, et al. 140-OR: Durable Glycemic Control and Elimination of Exogenous Insulin Use with VX-880 in Patients with Type 1 Diabetes (T1D)—VX-880-101 (FORWARD). Diabetes. 2025;74(Supplement_1). doi:10.2337/db25-140-or

BibTeX
@article{RICKELS2025,
  author = {RICKELS, MICHAEL R. and WITKOWSKI, PIOTR and REICHMAN, TREVOR W. and KONING, EELCO J. DE and MARKMANN, JAMES F. and ODORICO, JON S. and WIJKSTROM, MARTIN and KEAN, LESLIE S. and MATHIEU, CHANTAL and PETERS, ANNE L. and TAN, YAOYUAN VINCENT and VANIJCHAROENKARN, KRISTINE and MELTON, DOUGLAS and PAGLIUCA, FELICIA and BRUINSMA, BOTE and MARIGOWDA, GAUTHAM and RICORDI, CAMILLO},
  title = {140-OR: Durable Glycemic Control and Elimination of Exogenous Insulin Use with VX-880 in Patients with Type 1 Diabetes (T1D)—VX-880-101 (FORWARD)},
  journal = {Diabetes},
  year = {2025},
  volume = {74},
  number = {Supplement_1},
  doi = {10.2337/db25-140-or}
}
Kostenlos starten →